Fig. 1: Targeting TLR4–MD2 signalling in fibroblast activation. | Nature Reviews Rheumatology

Fig. 1: Targeting TLR4–MD2 signalling in fibroblast activation.

From: Targeting the TLR4–MD2 axis in systemic sclerosis

Fig. 1

Damage-associated molecular patterns (DAMPs) such as tenascin C signal via Toll-like receptor 4 (TLR4), which requires the accessory protein MD2 for signalling to occur, thereby activating various downstream signalling molecules that ultimately lead to the differentiation of fibroblasts to myofibroblasts and to fibrosis. Inhibiting MD2 using T5342126 attenuated fibrosis mediated by TLR4 stimulation. TRAM, TRIF-related adapter molecule; TRIF, TIR domain-containing adapter protein inducing interferon-β.

Back to article page